Vision Sessions


To view PPTicon-web  PowerPoint presentations click here.

Vision Sessions provide an in-depth examination of innovative programs and strategies designed to educate, mitigate and resolve issues related to Rx drug abuse and heroin use across the country. Participants will have an opportunity to engage leaders from organizations focused on prevention, intervention, policy development, healthcare, law enforcement, economic development and coalition-building. These sessions will outline new strategies stakeholders may implement to combat Rx drug abuse and heroin use on multiple fronts.

There are 10 Vision Sessions on Tuesday, March 29, starting at 8:00 am. Two additional sessions are also planned – one at 11:15 am on Tuesday and a second as part of the Federal Track on Wednesday, March 30, at 2:00 pm.

To learn more about individual breakout sessions click on the title name (updated 3-22-16):
 
American Medical Association Task Force to Reduce Opioid Abuse – Presented by American Medical Association
Brain Science Update: Non-Invasive, Non-Pharma Treatment for Chronic Pain and Opiate Drug Abuse – Presented by WestCare Foundation
Preventing Opioid Use and Abuse in High-Risk Patients – Presented by Educational Alliances in Clinical Medicine
Drug Treatment Courts: How America’s Most Trusted Alternative to Incarceration is Providing Hope in the Midst of the Rx Drug Abuse and Opiate Epidemic – Presented by National Association of Drug Court Professionals
NARxCHECK – The Next Generation of Controlled Substance Prescription History Reports for the Healthcare Professional – Presented by Appriss
Rescuing the Opiate Overdose: From Receptors to Relatives to Regulations – Presented by University of Kentucky HealthCare
Genetics-Based Solution to Substance Abuse Treatment – Presented by CAL Laboratories
Monitoring PDMP Effectiveness Now and in the Future – Presented by Health Information Designs
Using Social Media to Address Rx Drug Abuse in the Appalachian Region – Presented by the Appalachian Regional Commission
Addiction Is A Disease, Not A Choice, And Should Be Treated As Such – Presented by CLAAD
Struggle to Strength: Financial Capability on the Road to Recovery – Presented by Community Ventures and eHome America
The Importance of Collaboration Between State Leaders and the Medical Community to Reduce Opioid Abuse – Presented by National Association of Attorneys General
American Medical Association Task Force to Reduce Opioid Abuse
Tuesday, March 29, 2016, 8:00 am – 8:45 am
  Presented by:
American Medical Association
Presenter: Patrice A. Harris, MD, MA
Chair-Elect, American Medical Association Board of Trustees
Session Description The American Medical Association Task Force to Reduce Opioid Abuse, launched in 2015, represents the first national effort of organized medicine to coordinate and collaborate on a comprehensive approach to America’s opioid epidemic. The task force, comprised of more than 25 state, specialty and national organizations, is working to ensure effective pain management practices and evidence-based prescribing of opioids, promote appropriate referrals and access to care for patients with opioid use disorders, and take necessary steps needed to reduce opioid-related harm. This also includes efforts to increase physicians’ registration and use of Rx drug monitoring programs as well as promote enhanced education and training to help physicians become better educated about evidence-based care and appropriate prescribing practices. The presentation will detail the task force efforts and provide an update on how the nation’s medical societies have responded.
Return to the top
Brain Science Update: Non-Invasive, Non-Pharma Treatment for Chronic Pain and Opiate Drug Abuse
Tuesday, March 29, 2016, 8:00 am – 8:45 am
  Presented by:
WestCare Foundation
Presenters Yi Jin, MD
Founder and Chief Medical Officer, Newport Brain Research Lab
 
Judi Kosterman, PhD
Senior Vice President, WestCare Foundation
Session Description An update to the latest in neuroscience practice of medicine now bringing non-invasive, non-pharma, Magnetic Resonance Therapy (MRT) treatment to chronic pain and opiate drug abuse will be presented. Outcome data describing the results occurring with workers compensation patients will be presented along with the early outcomes of this work occurring within the U.S. Department of Veterans Affairs. In addition to hearing from the founders of this treatment protocol and those advancing it in both private and public sectors, attendees will have the opportunity to hear directly from patients themselves, including our nation’s veterans, who will tell “the rest of the story.”
Return to the top
Preventing Opioid Use and Abuse in High-Risk Patients
Tuesday, March 29, 2016, 8:00 am – 8:45 am
  Presented by:
Educational Alliances in Clinical Medicine
Presenters Margaret “Peggy” Compton, RN, PhD, FAAN
Professor and Associate Dean, Georgetown University School of Nursing and Health Studies
 
Michael F. Weaver, MD, FASAM
Medical Director, Center for Neurobehavioral Research on Addiction, University of Texas Health Science Center
Session Description The misuse and abuse of Rx opioids in the United States constitute a public health crisis that has grown to epidemic proportions over the last decade. The Centers for Disease Control and Prevention (CDC) identified Rx drug abuse and overdose as one of the top five health threats for 2014. The costs of Rx opioid abuse represent a substantial and growing economic burden for the U.S. healthcare system. The increasing prevalence of abuse suggests an even greater societal burden in the future. In an era of personalized medicine, current pain management protocols are still one-size-fits-all; therefore, new approaches are needed for pain management and related symptoms, with the aim of minimizing the potential for substance abuse. This presentation has been created to educate professionals from local, state and federal agencies, businesses, academia, clinicians, treatment providers, counselors and educators on strategies to prevent overuse and abuse of opioids in pain management.
Return to the top
Drug Treatment Courts: How America’s Most Trusted Alternative to Incarceration is Providing Hope in the Midst of the Rx Drug Abuse and Opiate Epidemic
Tuesday, March 29, 2016, 8:00 am – 8:45 am
  Presented by:
National Association of Drug Court Professionals
Presenter Terrence D. Walton, MSW, CSAC
Chief Operating Officer, National Association of Drug Court Professionals
Session Description Since 1989, drug treatment courts have been at the forefront of providing research-based options for justice system-involved individuals who are living with crippling substance use disorders. As the nation grapples with the precipitous rise in Rx, heroin and other opiate use, life-saving drug treatment courts are more essential than ever. Through drug treatment courts, individuals who are at high risk for treatment failure, repeat incarceration and drug-related death find paths of long-term recovery. Historically, these programs have successfully confronted the crack cocaine scourge of the 80’s and 90’s; the methamphetamine explosion that erupted in the new millennium; and the enduring problems caused by addiction-driven alcohol use. This vision session will survey how the justice and behavior health systems, led by drug treatment courts, are acting affirmatively to both prevent and treat the harms caused by the rise in opiate use nationwide.
Return to the top
NARxCHECK – The Next Generation of Controlled Substance Prescription History Reports for the Healthcare Professional
Tuesday, March 29, 2016, 8:00 am – 8:45 am
  Presented by:
Appriss
Presenters Carl Flansbaum
Director of Client Relationships and Government Affairs, Appriss
 
James E. “Jim” Huizenga, MD
Emergency Medical Physician
 
Bruce Jones, DO, FACEP
Medical Director, OhioHealth Doctors Hospital
Session Description Even as prescription (drug) monitoring programs (PMPs or PDMPs) have indeed become acknowledged as important tools in discovering potential abuse, misuse or diversion of controlled substances, analyzing the data provided can be challenging. Many times the “PMP request report” detailing a person’s controlled substance prescription history is data intensive, and therefore time consuming for a physician (or other prescriber) or pharmacist to review. However, reviewing and understanding this information is necessary (and in many cases mandatorily required) in order to make a clinical decision of whether or not to prescribe or dispense a controlled substance medication. This speaking panel provides an introduction to the next generation of these PMP request reports that can be generated from data contained in a prescription monitoring program. On hand will be the creator of the NARxCHECK reporting solution, as well as an emergency room physician who implemented this particular solution. Through NARxCHECK, authorized prescribers and pharmacists are additionally presented advanced analytics and graphical representations of PMP data. This allows for improved and more efficient comprehension of a person’s complete controlled substance prescription history in order to both improve patient safety as well as identify potential controlled substance prescription misuse and/or abuse. The panel will be interactive and open to questions from the audience.
Return to the top
Rescuing the Opiate Overdose: From Receptors to Relatives to Regulations
Tuesday, March 29, 2016, 8:00 am – 8:45 am
  Presented by:
University of Kentucky HealthCare
Presenters Catherine Martin, MD
Child and Adolescent Psychiatrist, University of Kentucky College of Medicine
 
Daniel Wermeling, PharmD
Professor of Pharmacy, University of Kentucky College of Pharmacy
Session Description Dr. Dan Wermeling and Dr. Catherine Martin will discuss the steps needed to rescue opiate overdoses. They will examine what works and bridges and barriers to implement effective treatment in a broader scale. Key issues will include naloxone delivery, drug product selection considerations, families, community interventions and legislative imperatives.
Return to the top
Genetics-Based Solution to Substance Abuse Treatment
Tuesday, March 29, 2016, 8:00 am – 8:45 am
  Presented by:
CAL Laboratories
Presenter Samantha Carr, CFRE, C-FA
Clinical Liaison, PR Director, Legislative Agent and Addiction Medicine Advocate, CAL Laboratory
Session Description Successfully addressing the epidemic of substance abuse within the United States requires specialized medical care. A critical factor in the development of an effective treatment plan is the utilization of appropriately prescribed medication. This session is designed to address the benefits of pharmacogenetic testing on predicting how a substance abuse patient will respond to drug therapy and provides valuable insight when choosing appropriate medication and dosage levels based off the patient’s genetic makeup. These benefits include: 1) improves patient outcomes by assisting in prescribing behavior; 2) minimizes negative drug interactions; and 3) minimizes cost of therapy.
Return to the top
Monitoring PDMP Effectiveness Now and in the Future
Tuesday, March 29, 2016, 8:00 am – 8:45 am
  Presented by:
Health Information Designs
Presenters John Felton
PMP Client Manager, Health Information Designs
 
Jennifer Posey, PMP, CTT+, MCTS
Interoperability Solutions Manager, Health Information Designs
 
Rebecca Poston, MHL
Program Manager, Florida Prescription Drug Monitoring Program
Session Description HID’s presentation will review how collaborative partnerships and data enhancements within current Rx monitoring programs are effective tools for protecting public health and safety while supporting sound clinical prescribing, dispensing, and use of controlled substances. Attendees will gain a better understanding of how actionable information maintained in a PDMP can be utilized in a variety of practice settings to improve patient health outcomes now and in the ever-changing healthcare environment of the future. Highlighted throughout the presentation will be the incredible success of E-FORCSE, the State of Florida’s PDMP which has seen real, tangible, positive outcomes since 2010 when the program began and HID’s RxSentry solution was implemented. Over the last five years, Florida has seen a 59 percent decrease in overall Rx drug-related death and a nearly 69 percent decrease in oxycodone related deaths, as well as a 65 percent reduction in the rate of multiple provider episodes over a 90-day period. Ms. Poston will present these and other successes experienced by the state. The session will end with information regarding the future of information sharing across the industry, including why public and private health plans need PDMP data, how the ONC’s Interoperability Roadmap will change the ways PDMP data is accessed, and more.
Return to the top
Using Social Media to Address Rx Drug Abuse in the Appalachian Region
Tuesday, March 29, 2016, 8:00 am – 8:45 am
  Presented by:
Appalachian Regional Commission
Presenters Kristin Mattson, MPH, CHES
Health Communication Specialist, Oak Ridge Associated Universities
 
Jennifer Reynolds, MPH, CHES
Health Communication Specialist, Oak Ridge Associated Universities
Session Description This session invites organizations working in the Appalachian region to learn about social and digital communications strategies that can help in the fight against Rx drug abuse and opioid overdose. Effective social media campaigns can be especially challenging in Appalachia’s rural and economically distressed communities. Through presentations and facilitated discussion, this session will explore the question: “How can Appalachian substance abuse organizations develop a successful social media strategy?” The program will also introduce an opportunity for Appalachian organizations to participate in an upcoming pilot Social Media Training and Technical Assistance Program, offered by the Appalachian Regional Commission, Center for Disease Control and Prevention’s National Center for Injury Prevention and Control, and Oak Ridge Associated Universities.
Return to the top
Addiction Is A Disease, Not A Choice, And Should Be Treated As Such
Tuesday, March 29, 2016, 8:00 am – 8:45 am
  Presented by:
CLAAD (Center for Lawful Access and Abuse Deterrence)
Presenters Genie L. Bailey, MD, DABAM
Associate Clinical Professor of Psychiatry and Human Behavior, Brown University, and Director of Research and Medical Director of Dual Diagnosis Unit, Stanley Street Treatment and Resources
 
Van Ingram
Executive Director, Kentucky Office of Drug Control Policy
 
Frank Vocci, PhD
President and Senior Research Scientist, Friends Research Institute
Session Description Reductions in the supply of medications available for abuse must be matched by corresponding decreases in demand. Demand reduction is imperative to prevent substance use disorders (SUDs) from developing or progressing and must be facilitated through public awareness, prescriber education and improved access to treatment. A SUD is a fundamental, yet treatable, disease of the brain. SUDs are comparable to other chronic medical conditions, such as hypertension, diabetes and asthma, and should be treated as such, with medication when appropriate. Clinical evidence supports that medications approved by the U.S. Food and Drug Administration for treating opioid dependence, when used in medication-assisted treatment (MAT), are safe and effective in treating SUDs. Additionally, MAT has been shown to be effective in reducing drug-related disease and criminal recidivism, leading to a recent push for the use of MAT in drug courts, jails and prisons throughout the country. In this presentation, speakers will discuss the available medications for treatment of opioid use disorder and research towards new treatments. Presenters will also address the need for access to treatment through third-party payers, the criminal justice system, and the need to adjust federal policy to improve treatment capacity.
Return to the top
Return to the top
Struggle to Strength: Financial Capability on the Road to Recovery
Tuesday, March 29, 2016, 11:15 am – 12:30 pm
  Presented by:
Community Ventures and eHome America
Presenters Milt Sharp, Jr.
President, eHome America, Community Ventures Corporation
Session Description “Real Resources, real solutions.” The goal of eHome Network is to create, for its agency partners, the tools necessary to provide the best education and counseling experience to clients, and to help partners operate more efficiently and effectively. Strategies to help those in recovery overcome their financial struggles will be shared during this session
Return to the top
The Importance of Collaboration Between State Leaders and the Medical Community to Reduce Opioid Abuse
Wednesday, March 30, 2016, 2:00 pm – 3:15 pm
  Presented by:
National Association of Attorneys General
Presenters Honorable Samuel “Sam” Olens, JD
Attorney General, State of Georgia
 
Yngvild Olsen, MD, MPH
Medical Director, Institutes for Behavior Resources, Inc.
 
Honorable Brad Schimel, JD
Attorney General, State of Wisconsin
Session Description While the jurisdiction of state attorneys general varies, all attorneys general have been on the frontline of combating opioid trafficking and addiction in their states and territories through increasing public awareness, decreasing stigma, and working with stakeholders to tackle this epidemic. Some of the most important stakeholders in this crisis are those in the medical community. This panel, which includes two attorneys general who have made addressing opioid addiction a priority in their states, and the Director-at-Large of the American Society of Addiction Medicine, will highlight the importance of collaboration between the medical and legal communities and describe some innovative policies and strategies, prescriber education initiatives, the expansion of prescription drug monitoring programs, and the need to reduce the stigma associated with addiction.
Return to the top
The content of these Vision Sessions are subject to change.